- Details
- Andrew Hsieh highlights his team's research on a new tumor suppressor mechanism termed transcriptional-translational conflict. The research primarily focuses on ARID1A, a component of the SWI/SNF chromatin remodeling complex, which is frequently deregulated in bladder cancer. In absence of ARID1A, up-regulated oncogenic gene networks were observed, but no tumorigenesis occurred due to a conflict b...
|
- Details
- Andrea Miyahira interviews John Lee about his team's publication in Nature Communications. Dr. Lee discusses the focus of their research on a protein called STEAP1, known to be enriched in prostate cancers and the target of substantial therapeutic development. He provides an overview of previous efforts, such as Genentech's discontinued ADC, and ongoing developments like Amgen's AMG 509. The resea...
|
- Details
- In a discussion hosted by Andrea Miyahira, David Quigley discusses his team's research on the genomic and epigenomic landscape of double-negative metastatic prostate cancer. Dr. Quigley provides insights into the mechanisms behind the disease's resistance to targeted therapy, highlighting the transformation of prostate adenocarcinoma cells towards either maintaining their original nature or transi...
|
- Details
- Andrea Miyahira and Susan Halabi discuss Dr Halabi's prognostic model for overall survival in patients with metastatic castration-resistant prostate cancer. Originating in the early 2000s, the model sought to provide patients with more specific information about their prognoses and categorize them into different risk groups. Dr. Halabi's model comprises eight easily obtainable clinical variables,...
|
- Details
- In this conversation, Andrea Miyahira is joined by a research team including Anke Augspach, Rahul Kanadia, and Mark Rubin. They discuss their paper, "Minor Intron Splicing is Critical for Survival of Lethal Prostate Cancer". The paper dissects the role of minor introns, which constitute less than 0.5% of all introns, in gene expression and their involvement in prostate cancer onset and progression...
|
- Details
- Christina Guo elaborates on her and her colleagues' findings published in European Urology, titled "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer". Dr. Guo's research focuses on B7-H3, an immunomodulatory glycoprotein overexpressed in prostate cancers. The team investigated B7-H3 expression in treatment-naive and castration-resistant prostate cancer biopsies, analyzing the protein's co...
|
- Details
- Gavin Ha and Andrea Miyahira discuss Ha's research into the transcriptional regulation of advanced prostate cancer phenotypes. Dr. Ha's team uses circulating tumor DNA (ctDNA) in liquid biopsies to overcome challenges with traditional tumor biopsies in metastatic cancer patients. The focus of the research is on tumor phenotype, which may reveal why some tumors resist certain therapies. A new tool...
|
- Details
- Andrea Miyahira invites Di Zhao to discuss her research published in Science Translational Medicine entitled “Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.” Dr. Zhao's team explored immune checkpoint B7-H3, identified as a promising target for advanced prostate cancer with PTEN and p53 deficiencies. Their analysis of immune checkpoi...
|
- Details
- Andrea Miyahira speaks with Arianna Calcinotto and Nicolo Bancaro about their groundbreaking research on the role of senescent neutrophils in prostate cancer. Calcinotto's team discovered that prostate tumor cells produce a molecule, ApoE, which can bind to and influence a type of immune cells, neutrophils, resulting in these cells acquiring senescent, or aged features. They also found that these...
|
- Details
- In a conversation with Andrea Miyahira, Eugene Shenderov discusses the recent study conducted by his team and published under the title, “Neoadjuvant Enoblituzumab in Localized Prostate Cancer: A Single-Arm, Phase II Trial.” In the past, immunotherapies have demonstrated limited efficacy in prostate cancer treatment. This is primarily due to the necessity for selective immunotherapy in this settin...
|
